AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01888822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prophylactic placebo infusion before elective laparoscopic cholecystectomy
Study NCT01889498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide twice a day, at 12 hour intervals:~* 250 mg Tablets; one tablet to be taken twice daily from three days before the day of surgery~* One tablet to take two hours before surgery~* 500mg Intravenous Acetazolamide; to be administered upon arrival in critical care post-surgery; continuing at 12 hour intervals until last acetazolamide administration at 72 hours.
Study NCT01860521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Programmed Intermittent Epidural Bolus
Description: An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was \< 30 mm were administered.
Study NCT01860521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Epidural Infusion
Description: An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was \< 30 mm were administered.
Study NCT01860521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure of interruption of pregnancy
Description: Patients were administered 1 mg of gemeprost pessaries (Cervidil®, Merck Serono SPA, Roma, Italy) in the posterior fornix of the vagina every 3 hours up to 5 doses. If the expulsion of the fetus did not occur, the therapeutic regimen was repeated after 24 hours from the initiation of the treatment. Induction-to-abortion time (hours) was considered the period of time comprised between the first gemeprost pessary administration and fetal expulsion. Failure of induction of abortion was defined as women undelivered after two completed cycles (48h).The evacuation of the uterus under general anesthesia was performed if ultrasonography showed retained productions of conception.
Study NCT01860521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug used for analgesia procedures
Description: Levobupivacaine (Chirocaine®, Abbott, Chicago, IL, USA) and sufentanil(Fentatienil®, Angelini, Rome, Italy) were administered in both study groups according to the regimen of each intervention arm (Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion).
Study NCT01860521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump for programmed intermittent bolus.
Description: Pump administering programmed intermittent epidural bolus for the maintenance of analgesia was used.
Study NCT01860521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump for continuous epidural infusion.
Description: Pump administering continuous epidural infusion for the maintenance of analgesia was used.
Study NCT01860521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug used for termination of pregnancy procedure.
Description: Gemeprost pessaries.
Study NCT04197765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: accelerated Thetaburst stimulation
Description: We will administer 20-30 treatment sessions over the course of the study. The study technician will place the coil over the Fp2 electrode of a 10-20 International EEG system hair net, to approximate stimulation of the R-OFC). For the first three treatments, the study psychiatrist will set treatment intensity to 90% MT, and gradually increase intensity to 120% MT over 20 seconds to maximize tolerability. Subsequent treatment sessions (treatment 4 and onward) will begin, and remain, at 120% MT.~Treatment will occur 4-5 times a day, separated by an at least 45-min interval between sessions on consecutive weekdays. We estimate all study-related treatments will be complete in 5-6 weekdays.
Study NCT04197765 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: All parameters will be programmed in the same way as active treatment, however, the treatment will be delivered on the side of the coil that has an internal (hidden) metal shield that will prevent magnetic energy from reaching the skull and brain. Neither the technician, treating physician, nor the patient, will know whether the treatment was delivered from the sham or active side of the coil. The same auditory and tactile cues will be present during active and sham treatment as electrodes will be placed on the scalps of each participant (whether receiving active or sham treatment) that deliver some electrical sensation.
Study NCT02982356 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fetal Selective Reduction Technology
Description: Fetal Selective Reduction Technology will be conducted according to different gestational weeks: before 16weeks, 16\~24 weeks, 24\~27+6 weeks,>28weeks
Study NCT02982356 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Potassium Chloride
Study NCT05742971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention performed through the Oculuc Go VR glasses
Description: The participants randomised into this group are offered a VR intervention during the external version for 5-10 minutes in addition to the standard care of an ECV. The VR is performed through the Oculus Go VR glasses. These women can choose for an immersive guided relaxation VR experience or an interactive VR experience (see descriptions below). The ECV expert executing the ECV will register immediately after the ECV which option the patients has chosen. Immediately after the external version, a pain measurement is taken with regard to the pain during the ECV by means of the NRS score. After the ECV procedure, participants of the VR-group receive a structured questionnaire in which tolerability, feasibility and satisfaction of VR use is evaluated.
Study NCT00685477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Sequence ABC
Description: Drug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes
Study NCT00685477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Sequence ACB
Description: Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes
Study NCT00685477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Sequence BAC
Description: Drug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion
Study NCT00685477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Sequence BCA
Description: Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion
Study NCT00685477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Sequence CAB
Description: Drug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion
Study NCT00685477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Sequence CBA
Description: Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion
Study NCT04222881 — intervention group
Intervention type: PROCEDURE
Intervention: AVF anastomosis
Description: Type of arteriovenous anastomosis
Study NCT02402738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy
Study NCT02402738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Study NCT04564768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness-Based Cancer Recovery (MBCR)
Description: Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
Study NCT02282345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02282345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study NCT03597646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Study NCT03597646 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold Inspiratory Muscle Trainer
Study NCT03303027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6-0 fast absorbing gut suture
Description: Fast absorbing surgical gut suture is a strand of collagenous material, size 6-0
Study NCT03303027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-0 fast absorbing gut suture
Description: Fast absorbing surgical gut suture is a strand of collagenous material, size 5-0
Study NCT03876301 — intervention group
Intervention type: DRUG
Intervention: Standard of Care FVIII Replacement therapy
Description: There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
Study NCT03023670 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiopulmonary bypass
Description: Low flow of mixed oxygen / air (1:1L) will be used during the period of cardiopulmonary bypass
Study NCT03023670 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiopulmonary bypass
Description: Low rate (4\\min) with low tidal volume ( 2ml/kg ) will be used during the period of cardiopulmonary bypass.
Study NCT02983097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m²
Study NCT02983097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatinum 100 mg / m²
Study NCT02983097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatinum AUC5
Study NCT02983097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg
Study NCT02983097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2000 mg/m², administered twice
Study NCT02983097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5-20 mg administered either d1-d7, or d-6-d7
Study NCT02983097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegFilgrastim
Description: PegFilgrastim 6 mg
Study NCT02983097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral stem cell collection
Description: collection of peripheral stem cells for autologous stem cell transplantation
Study NCT00924781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline
Description: MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
Study NCT00924781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline
Description: MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
Study NCT00924781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
Description: MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
Study NCT00499057 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: interstitial high dose-rate brachytherapy, PBI
Description: Single arm study Treatment schedule is 4 Gy twice a day, with a time relapse of at least 6 hours between each fraction, for four days, for a total dose 32 Gy.
Study NCT03779243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin 5mg and Sleep Education
Description: Melatonin 5mg daily and sleep education for 6 weeks following injury or surgery.
Study NCT03779243 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo pills for 6 weeks following injury or surgery.
Study NCT01155882 — intervention group
Intervention type: PROCEDURE
Intervention: Whipple at the Splenic Artery (WATSA)
Study NCT02802670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GDC-0810
Description: Participants will receive a single 300-mg dose of GDC-0810 containing approximately 100 microcuries of \[14C\]-labeled GDC-0810 on Day 1.
Study NCT00742781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral supplementation daily with up to 5000 IU over 6 months.
Study NCT01813175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular non-hydrolysed cow's milk II
Description: Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
Study NCT03312218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spaced educational intervention
Description: A spaced educational intervention will be provided to participants
Study NCT00991965 — intervention group
Intervention type: DEVICE
Intervention: INFUSE® Bone Graft
Description: Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
Study NCT01332864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: O OMT applied to areas of somatic dysfunction other than the head region.
Study NCT01813175 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular non-hydrolysed cow's milk - control
Description: Regular non-hydrolysed cow's milk based infant formula without synbiotics mixture
Study NCT01913353 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA BN®
Description: 0.5 ml MVA BN® with a nominal titer of 1x10E8 TCID50, administered as a subcutaneous injection
Study NCT01913353 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACAM2000®
Description: 0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.
Study NCT01913353 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACAM2000®
Description: 0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.
Study NCT02143648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine HCl ER tablets 60 mg BID
Description: nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks
Study NCT02143648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine HCl ER tablets 120mg BID
Description: nalbuphine HCl ER tablets 120mg BID administered for 6 weeks
Study NCT02143648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets BID
Description: Placebo tablets BID administered for 8 weeks
Study NCT04488952 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: nerve block combined with general anesthesia
Description: Patients in this group receive nerve block combined with general anesthesia.
Study NCT00267241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Four different types of assisted ventilation (pressure support, pressure support plus sigh, BIPAP, variable ventilation)
Study NCT02318004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Non invasive nocturnal monitoring of heart and respiratory rate and subjects movement out of bed.
Study NCT04710108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Communication
Description: Spoken word poem set to video images performed by author. Comic book was transformed from the video that was equivalent in content to the video.
Study NCT01836861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: Intravenous infusion: approximately 2.8 μg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145
Study NCT00566306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyhexamethyleneguanidine (PHMG)
Description: 6 months in 3 experimental wards
Study NCT02562729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve-Sparing Radical Hysterectomy
Description: Type C1 NSRH Removal indwelling catheter on day 4 after surgery
Study NCT01332864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: O OMT applied to areas of somatic dysfunction other than the head region.
Study NCT04488952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nerve block combined with general anesthesia
Description: Patients in this group receive nerve block combined with general anesthesia.
Study NCT04488952 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: spinal anesthesia
Description: Patients in this group receive spinal anesthesia.
Study NCT04488952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: Patients in this group receive spinal anesthesia.
Study NCT01182363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Solve Education
Description: Problem solving education (PSE), a brief skills-building psychotherapeutic intervention that focuses on specific daily problems, and applies to these problems a structured approach to finding and evaluating solutions, is one such problem solving approach. Problem solving education differs from other problem solving interventions in that it can be conducted by a variety of health providers, who do not have specific training as mental health clinicians. Sessions are fairly brief (approximately 30 minutes in length) and positive, sustained effects have been achieved in 6-8 sessions. Problem solving education's success is based on premise that strong problem solving abilities promote a sense of control and self-efficacy and buffer the negative effects of life stressors.
Study NCT03732547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 mAb
Description: Intravenous infusion of PD-1 mAb, 200mg, once a time, every three weeks.
Study NCT03732547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyIC
Description: Intramuscular injection of polyIC, 2mg, every other day, for three weeks.
Study NCT01332864 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Light touch
Description: Light touch applied to head region for 10 minutes with patient supine at rest.
Study NCT03430869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 AV-45
Description: In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by F-18 AV-45 PET.
Study NCT03430869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18-THK-5351
Description: In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. All subjects will further undergo F-18-THK-5351 image study to detect underlying tau pathology. By doing this, the investigators will elucidate the neurodegenerative pathophysiology behind the link between depressive disorder and the subsequent development of dementia.
Study NCT01305018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA
Description: 7 g of leucine + 3,5 g of isoleucine + 3,5 g of valine per day during 9 days
Study NCT01977287 — intervention group
Intervention type: DEVICE
Intervention: Functional Electrical Stimulation